IRWDIRONWOOD PHARMACEUTICALS INC
- Market cap
- $571.73M
- as of 2026-10-23
- Latest close
- $3.46
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Drug Manufacturers - Specialty & Generic
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2023-11-20
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Denner Alexander J | Sep 15 | Sep 17 | A | 3,694 | $0.00 | $0 | 327,549 | No | Form 4 |
| Silber JeffreySVP, CMO, Head-Res&Drug | Jul 20 | Jul 22 | A | 137,036 | $0.00 | $0 | 137,036 | No | Form 4 |
| Silver RonaldPFO & PAO | Jul 7 | Jul 9 | S | 127,890 | $4.52 | Sale −$578,063 | 313,680 | Yes | Form 4 |
| Moukheibir Catherine | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 181,425 | No | Form 4 |
| McHugh Julie | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 272,320 | Yes | Form 4 |
| McHugh Julie | Jun 16 | Jun 17 | S | 21,571 | $3.73 | Sale −$80,460 | 250,749 | Yes | Form 4 |
| Denner Alexander J | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 323,855 | No | Form 4 |
| Duane Jon R | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 253,820 | No | Form 4 |
| Currie Mark G | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 676,900 | No | Form 4 |
| Kessler Marla L | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 229,364 | No | Form 4 |
| Shepard Jay | Jun 16 | Jun 17 | A | 63,481 | $0.00 | $0 | 235,036 | No | Form 4 |
| Denner Alexander J | Jun 15 | Jun 17 | A | 4,065 | $0.00 | $0 | 260,374 | No | Form 4 |
| Silver RonaldPFO & PAO | May 19 | May 21 | A | 25,000 | $0.00 | $0 | 441,570 | No | Form 4 |
| Denner Alexander J | Mar 17 | Mar 17 | S | 6,725,000 | $3.05 | Sale −$20,511,250 | 9,194,435 | No | Form 4 |
| Denner Alexander J | Mar 17 | Mar 17 | S | 5,800 | $3.31 | Sale −$19,198 | 9,188,635 | No | Form 4 |
| Denner Alexander J | Mar 13 | Mar 17 | A | 4,451 | $0.00 | $0 | 256,309 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Mar 10 | Mar 12 | A | 409,836 | $0.00 | $0 | 1,898,838 | No | Form 4 |
| Martini Gregory S.Chief Financial Officer | Mar 10 | Mar 12 | A | 136,612 | $0.00 | $0 | 297,213 | No | Form 4 |
| John MinardoChief Legal Officer | Mar 10 | Mar 12 | A | 136,612 | $0.00 | $0 | 500,498 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Mar 10 | Mar 12 | A | 163,934 | $0.00 | $0 | 416,570 | No | Form 4 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Mar 10 | Mar 12 | A | 136,612 | $0.00 | $0 | 658,037 | No | Form 4 |
| Gaskins Tammi LChief Commercial Officer | Mar 10 | Mar 12 | A | 136,612 | $0.00 | $0 | 350,350 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Feb 24 | Feb 25 | S | 12,621 | $3.66 | Sale −$46,193 | 252,636 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Feb 24 | Feb 25 | S | 103,526 | $3.66 | Sale −$378,905 | 1,489,002 | No | Form 4 |
| Gaskins Tammi LChief Commercial Officer | Feb 24 | Feb 25 | S | 11,239 | $3.66 | Sale −$41,135 | 213,738 | No | Form 4 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Feb 24 | Feb 25 | S | 17,012 | $3.66 | Sale −$62,264 | 521,425 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 24 | Feb 25 | S | 19,053 | $3.66 | Sale −$69,734 | 363,886 | No | Form 4 |
| Martini Gregory S.Chief Financial Officer | Feb 24 | Feb 25 | S | 11,457 | $3.66 | Sale −$41,933 | 160,601 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Feb 23 | Feb 25 | S | 11,552 | $3.81 | Sale −$44,013 | 265,257 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Feb 23 | Feb 25 | S | 94,757 | $3.81 | Sale −$361,024 | 1,592,528 | No | Form 4 |
| Gaskins Tammi LChief Commercial Officer | Feb 23 | Feb 25 | S | 10,287 | $3.81 | Sale −$39,193 | 224,977 | No | Form 4 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Feb 23 | Feb 25 | S | 15,570 | $3.81 | Sale −$59,322 | 538,437 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 23 | Feb 25 | S | 17,439 | $3.81 | Sale −$66,443 | 382,939 | No | Form 4 |
| Martini Gregory S.Chief Financial Officer | Feb 23 | Feb 25 | S | 10,487 | $3.81 | Sale −$39,955 | 172,058 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Jan 5 | Jan 7 | S | 35,416 | $4.60 | Sale −$162,914 | 276,809 | Yes | Form 4 |
| Denner Alexander J | Dec 15, 2025 | Dec 17, 2025 | A | 4,178 | $0.00 | $0 | 251,858 | No | Form 4 |
| Gaskins Tammi LChief Commercial Officer | Nov 17, 2025 | Nov 19, 2025 | S | 6,016 | $3.32 | Sale −$19,973 | 235,264 | No | Form 4 |
| Denner Alexander J | Sep 15, 2025 | Sep 17, 2025 | A | 11,718 | $0.00 | $0 | 247,680 | No | Form 4 |
| Martini Gregory S.Chief Financial Officer | Aug 11, 2025 | Aug 13, 2025 | S | 1,265 | $0.84 | Sale −$1,063 | 182,545 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Aug 11, 2025 | Aug 13, 2025 | S | 2,846 | $0.84 | Sale −$2,391 | 276,809 | No | Form 4 |
| John MinardoChief Legal Officer | Aug 11, 2025 | Aug 13, 2025 | S | 7,754 | $0.84 | Sale −$6,513 | 400,378 | No | Form 4 |
| Gaskins Tammi LChief Commercial Officer | Aug 11, 2025 | Aug 13, 2025 | S | 1,316 | $0.84 | Sale −$1,105 | 241,280 | No | Form 4 |
| Sarissa Capital Management LP | Jun 13, 2025 | Jun 17, 2025 | A | 24,193 | $0.00 | $0 | 235,962 | No | Form 4 |
| Denner Alexander J | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 211,769 | No | Form 4 |
| Dreyfus Andrew | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 228,313 | No | Form 4 |
| McHugh Julie | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 208,839 | No | Form 4 |
| Currie Mark G | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 613,419 | No | Form 4 |
| Duane Jon R | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 190,339 | No | Form 4 |
| Moukheibir Catherine | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 117,944 | No | Form 4 |
| Shepard Jay | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 171,555 | No | Form 4 |
| Kessler Marla L | Jun 10, 2025 | Jun 12, 2025 | A | 45,000 | $0.00 | $0 | 165,883 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | May 20, 2025 | May 20, 2025 | A | 540,000 | $0.00 | $0 | 1,687,281 | No | Form 4 |
| Gaskins Tammi LChief Commercial Officer | May 16, 2025 | May 20, 2025 | S | 2,563 | $0.58 | Sale −$1,487 | 242,596 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | May 16, 2025 | May 20, 2025 | S | 13,353 | $0.58 | Sale −$7,745 | 1,147,281 | No | Form 4 |
| Sarissa Capital Management LP | Apr 2, 2025 | Apr 4, 2025 | A | 10,416 | $0.00 | $0 | 166,769 | No | Form 4 |
| Martini Gregory S.Chief Financial Officer | Feb 10, 2025 | Feb 12, 2025 | S | 12,052 | $1.76 | Sale −$21,212 | 183,810 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 10, 2025 | Feb 12, 2025 | A | 122,222 | $0.00 | $0 | 447,070 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 10, 2025 | Feb 12, 2025 | S | 38,938 | $1.76 | Sale −$68,531 | 408,132 | No | Form 4 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Feb 10, 2025 | Feb 12, 2025 | A | 133,333 | $0.00 | $0 | 595,276 | No | Form 4 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Feb 10, 2025 | Feb 12, 2025 | S | 41,269 | $1.76 | Sale −$72,633 | 554,007 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Feb 10, 2025 | Feb 12, 2025 | S | 12,048 | $1.76 | Sale −$21,204 | 279,655 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Feb 10, 2025 | Feb 12, 2025 | S | 139,064 | $1.76 | Sale −$244,753 | 1,160,634 | No | Form 4 |
| Martini Gregory S.Chief Financial Officer | Jan 27, 2025 | Jan 29, 2025 | A | 111,111 | $0.00 | $0 | 195,862 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Jan 27, 2025 | Jan 29, 2025 | A | 133,333 | $0.00 | $0 | 291,703 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Jan 17, 2025 | Jan 22, 2025 | A | 147,354 | $0.00 | $0 | 1,299,698 | No | Form 4 |
| John MinardoChief Legal Officer | Jan 17, 2025 | Jan 22, 2025 | A | 40,187 | $0.00 | $0 | 324,848 | No | Form 4 |
| Shetzline MichaelSVP, CMO, Head-Res&Drug | Jan 17, 2025 | Jan 22, 2025 | A | 48,224 | $0.00 | $0 | 461,943 | No | Form 4 |
| Sarissa Capital Management LP | Dec 16, 2024 | Dec 18, 2024 | A | 4,249 | $0.00 | $0 | 156,353 | No | Form 4 |
| Emany Sravan KumarSVP, COO and CFO | Nov 18, 2024 | Nov 20, 2024 | S | 11,001 | $4.08 | Sale −$44,884 | 309,572 | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Nov 18, 2024 | Nov 20, 2024 | S | 5,360 | $4.08 | Sale −$21,869 | 284,685 | No | Form 4 |
| Sarissa Capital Management LP | Sep 16, 2024 | Sep 18, 2024 | A | 3,282 | $0.00 | $0 | 152,104 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Aug 12, 2024 | Aug 14, 2024 | S | 3,107 | $4.27 | Sale −$13,267 | 158,370 | No | Form 4 |
| John MinardoChief Legal Officer | Aug 12, 2024 | Aug 14, 2024 | S | 9,910 | $4.27 | Sale −$42,316 | 284,661 | No | Form 4 |
| Currie Mark G | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 568,419 | No | Form 4 |
| Kessler Marla L | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 120,883 | No | Form 4 |
| Duane Jon R | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 145,339 | No | Form 4 |
| McHugh Julie | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 163,839 | No | Form 4 |
| Dreyfus Andrew | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 188,230 | No | Form 4 |
| Shepard Jay | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 126,555 | No | Form 4 |
| Denner Alexander J | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 148,822 | No | Form 4 |
| Moukheibir Catherine | Jun 18, 2024 | Jun 21, 2024 | A | 24,311 | $0.00 | $0 | 72,944 | No | Form 4 |
| Sarissa Capital Management LP | Jun 15, 2024 | Jun 18, 2024 | A | 2,572 | $0.00 | $0 | 124,511 | No | Form 4 |
| McHugh Julie | Jun 10, 2024 | Jun 12, 2024 | S | 22,766 | $6.29 | Sale −$143,198 | 139,528 | Yes | Form 4 |
| Moukheibir Catherine | Jun 7, 2024 | Jun 10, 2024 | S | 35,574 | $6.61 | Sale −$235,144 | 48,633 | No | Form 4 |
| Moukheibir Catherine | Jun 6, 2024 | Jun 10, 2024 | S | 44,426 | $6.36 | Sale −$282,549 | 84,207 | No | Form 4 |
| John MinardoChief Legal Officer | May 20, 2024 | May 22, 2024 | S | 17,404 | $6.45 | Sale −$112,256 | 294,571 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | May 20, 2024 | May 22, 2024 | S | 16,128 | $6.45 | Sale −$104,026 | 413,719 | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | May 20, 2024 | May 22, 2024 | S | 22,725 | $6.45 | Sale −$146,576 | 288,031 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | May 20, 2024 | May 22, 2024 | S | 67,618 | $6.45 | Sale −$436,136 | 1,150,330 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | May 16, 2024 | May 20, 2024 | F | 18,280 | $6.64 | $121,379 | 320,573 | No | Form 4 |
| Denner Alexander J | Mar 15, 2024 | Mar 19, 2024 | A | 1,662 | $0.00 | $0 | 121,939 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | Mar 8, 2024 | Mar 12, 2024 | M | 34,936 | $0.00 | $0 | 429,847 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | Mar 8, 2024 | Mar 12, 2024 | M · derivative | 34,936 | $0.00 | $0 | not reported | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Mar 8, 2024 | Mar 12, 2024 | M | 37,120 | $0.00 | $0 | 338,853 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Mar 8, 2024 | Mar 12, 2024 | M · derivative | 37,120 | $0.00 | $0 | not reported | No | Form 4 |
| John MinardoChief Legal Officer | Mar 8, 2024 | Mar 12, 2024 | M | 32,752 | $0.00 | $0 | 311,975 | No | Form 4 |
| John MinardoChief Legal Officer | Mar 8, 2024 | Mar 12, 2024 | M · derivative | 32,752 | $0.00 | $0 | not reported | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Mar 8, 2024 | Mar 12, 2024 | M | 120,298 | $0.00 | $0 | 1,217,948 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Mar 8, 2024 | Mar 12, 2024 | M · derivative | 120,298 | $0.00 | $0 | not reported | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Mar 8, 2024 | Mar 12, 2024 | M | 37,120 | $0.00 | $0 | 310,756 | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Mar 8, 2024 | Mar 12, 2024 | M · derivative | 37,120 | $0.00 | $0 | not reported | No | Form 4 |
| Duane Jon R | Mar 6, 2024 | Mar 8, 2024 | P | 6,920 | $8.70 | Purchase +$60,204 | 121,028 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Mar 5, 2024 | Mar 7, 2024 | A | 264,876 | $0.00 | $0 | 1,097,650 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Mar 5, 2024 | Mar 7, 2024 | A · derivative | 132,438 | $0.00 | $0 | 132,438 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Mar 4, 2024 | Mar 6, 2024 | P | 10,684 | $9.38 | Purchase +$100,216 | 301,733 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Feb 12, 2024 | Feb 14, 2024 | S | 177,164 | $15.24 | Sale −$2,699,979 | 832,774 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Feb 12, 2024 | Feb 14, 2024 | A | 65,312 | $0.00 | $0 | 291,049 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Feb 12, 2024 | Feb 14, 2024 | A · derivative | 32,656 | $0.00 | $0 | 32,656 | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Feb 12, 2024 | Feb 14, 2024 | S | 9,846 | $15.24 | Sale −$150,053 | 208,324 | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Feb 12, 2024 | Feb 14, 2024 | A | 65,312 | $0.00 | $0 | 273,636 | No | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Feb 12, 2024 | Feb 14, 2024 | A · derivative | 32,656 | $0.00 | $0 | 32,656 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Feb 12, 2024 | Feb 14, 2024 | S | 7,908 | $15.24 | Sale −$120,518 | 134,264 | No | Form 4 |
| Silver RonaldPrincipal Accounting Officer | Feb 12, 2024 | Feb 14, 2024 | A | 27,213 | $0.00 | $0 | 161,477 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | Feb 12, 2024 | Feb 14, 2024 | S | 38,618 | $15.24 | Sale −$588,538 | 340,484 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | Feb 12, 2024 | Feb 14, 2024 | A | 54,427 | $0.00 | $0 | 394,911 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | Feb 12, 2024 | Feb 14, 2024 | A · derivative | 27,214 | $0.00 | $0 | 27,214 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 12, 2024 | Feb 14, 2024 | S | 47,380 | $15.24 | Sale −$722,071 | 224,796 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 12, 2024 | Feb 14, 2024 | A | 54,427 | $0.00 | $0 | 279,223 | No | Form 4 |
| John MinardoChief Legal Officer | Feb 12, 2024 | Feb 14, 2024 | A · derivative | 27,214 | $0.00 | $0 | 27,214 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Feb 8, 2024 | Feb 12, 2024 | F | 41,332 | $14.90 | $615,847 | 225,737 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Jan 17, 2024 | Jan 19, 2024 | A | 85,000 | $0.00 | $0 | 267,069 | No | Form 4 |
| John MinardoChief Legal Officer | Jan 17, 2024 | Jan 19, 2024 | A | 79,981 | $0.00 | $0 | 272,176 | No | Form 4 |
| Shetzline MichaelCMO,SVP,Head-Res&Drug | Jan 17, 2024 | Jan 19, 2024 | A | 57,971 | $0.00 | $0 | 379,102 | No | Form 4 |
| MCCOURT Thomas AChief Executive Officer | Jan 17, 2024 | Jan 19, 2024 | A | 249,617 | $0.00 | $0 | 1,009,938 | No | Form 4 |
| Sarissa Capital Management LP | Dec 15, 2023 | Dec 19, 2023 | A | 1,347 | $0.00 | $0 | 120,277 | No | Form 4 |
| Moukheibir Catherine | Dec 15, 2023 | Dec 19, 2023 | A | 1,572 | $0.00 | $0 | 128,633 | No | Form 4 |
| Kessler Marla L | Dec 14, 2023 | Dec 18, 2023 | S | 9,926 | $11.19 | Sale −$111,072 | 96,572 | Yes | Form 4 |
| Davis AndrewSVP, Chief Business Officer | Nov 20, 2023 | Nov 22, 2023 | S | 3,287 | $9.69 | Sale −$31,851 | 217,374 | No | Form 4 |
| Emany Sravan KumarSVP, Chief Financial Officer | Nov 16, 2023 | Nov 20, 2023 | F | 6,661 | $9.44 | $62,880 | 182,069 | No | Form 4 |